Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

BACKGROUND: Although sorafenib is the global standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC), it does not have reliable predictive or prognostic biomarkers. Circulating cell-free DNA (cfDNA) has shown promise as a biomarker for various cancers. We investigated...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BMC Cancer
Main Authors: Oh, Chung Ryul, Kong, Sun-Young, Im, Hyeon-Su, Kim, Hwa Jung, Kim, Min Kyeong, Yoon, Kyong-Ah, Cho, Eun-Hae, Jang, Ja-Hyun, Lee, Junnam, Kang, Jihoon, Park, Sook Ryun, Ryoo, Baek-Yeol
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2019
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6444867/
https://ncbi.nlm.nih.gov/pubmed/30935424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5483-x
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים